Natural history of human immunodeficiency virus disease in perinatally infected children: an analysis from the Pediatric Spectrum of Disease Project.

OBJECTIVE To describe the progression of human immunodeficiency virus (HIV) disease through clinical stages from birth to death among a large number of perinatally infected children. METHODS The Pediatric Spectrum of Disease (PSD) project, coordinated by the Centers for Disease Control and Prevention (CDC), has conducted active surveillance for HIV disease since 1988 in seven geographic regions. PSD data are collected from medical and social service records every 6 months through practitioners at each participating hospital clinic. We analyzed data from perinatally HIV-infected children born between 1982 and 1993. The natural history of HIV disease was divided into five progressive stages using the clinical categories in the CDC 1994 pediatric HIV classification system: stage N, no signs or symptoms; stage A, mild signs or symptoms; stage B, moderate signs or symptoms; stage C, severe signs or symptoms; and stage D, death. A five-stage Markov model was fitted to the PSD data. To compare the estimates from the PSD project with the published estimates, we also fitted an alternative Markov model using acquired immunodeficiency syndrome (AIDS; 1987 case definition) in place of stage C and also calculated standard Kaplan-Meier estimates. RESULTS A total of 2148 perinatally HIV-infected children were included in the analysis. The estimated mean times spent in each stage were: N, 10 months; A, 4 months; B, 65 months; and C, 34 months. We estimated that a child born with HIV infection has a 50% (95% confidence interval [CI], 40%-60%) chance of severe signs or symptoms developing by 5 years of age and a 75% (95% CI, 68%-82%) chance of surviving to 5 years of age. For a child in stage B, there is a 60% (95% CI, 49%-71%) chance of severe signs or symptoms developing within the next 5 years and a 65% (95% CI, 56%-73%) chance of surviving 5 more years. The estimated mean time from birth to stage C was 6.6 (95% CI, 5.7-7.5) years, and the estimated mean survival time from birth was 9.4 (95% CI, 8.1-10.7) years. From the alternative Markov model, the estimated mean time from birth to AIDS was 4.8 (95% CI, 4.5-5.2) years. CONCLUSION Markov modeling using the revised pediatric classification system allowed us to describe the natural history of HIV disease in children before diagnosis of AIDS. On average, children progress to moderate symptoms in the second year of life and then remain moderately symptomatic for more than half of their expected lives, underscoring their need for clinical care before the onset of AIDS. The results from the Markov model are useful in family counseling, health care planning, and clinical trial designs.

[1]  A. Spira,et al.  Natural history of human immunodeficiency virus type 1 infection in children: prognostic value of laboratory tests on the bimodal progression of the disease. , 1992, The Pediatric infectious disease journal.

[2]  I M Longini,et al.  Effect of routine use of therapy in slowing the clinical course of human immunodeficiency virus (HIV) infection in a population-based cohort. , 1993, American journal of epidemiology.

[3]  F. Deist,et al.  A Prospective Study of Infants Born to Women Seropositive for Human Immunodeficiency Virus Type I , 1990 .

[4]  J F Lawless,et al.  Multi-state Markov models for analysing incomplete disease history data with illustrations for HIV disease. , 1994, Statistics in medicine.

[5]  F. Deist,et al.  Longitudinal study of 94 symptomatic infants with perinatally acquired human immunodeficiency virus infection. Evidence for a bimodal expression of clinical and biological symptoms. , 1990, American journal of diseases of children.

[6]  I. Longini,et al.  Estimating the stage-specific numbers of HIV infection using a Markov model and back-calculation. , 1992, Statistics in medicine.

[7]  V. De Gruttola,et al.  Incubation periods for paediatric AIDS patients , 1988, Nature.

[8]  R Kay,et al.  A Markov model for analysing cancer markers and disease states in survival studies. , 1986, Biometrics.

[9]  J. Ward,et al.  Statistical analysis of the stages of HIV infection using a Markov model. , 1989, Statistics in medicine.

[10]  H. Jaffe,et al.  Acquired immunodeficiency syndrome in children: report of the Centers for Disease Control National Surveillance, 1982 to 1985. , 1987, Pediatrics.

[11]  A. Plebani,et al.  Prognostic factors and survival in children with perinatal HIV-1 infection , 1992, The Lancet.

[12]  I M Longini,et al.  The dynamics of CD4+ T-lymphocyte decline in HIV-infected individuals: a Markov modeling approach. , 1991, Journal of acquired immune deficiency syndromes.

[13]  J. Kalbfleisch,et al.  Estimation in Markov models from aggregate data. , 1983, Biometrics.

[14]  M H Gail,et al.  Evaluating serial cancer marker studies in patients at risk of recurrent disease. , 1981, Biometrics.

[15]  H. Southwick,et al.  The Medical Center. , 1980, The Proceedings of the Institute of Medicine of Chicago.

[16]  M. Zelen,et al.  Semi-Markov models for partially censored data , 1978 .